Professor Peter Hillmen, Leeds, UK

Professor Robert Mansson, Karolinska, Sweden

Professor Adam Mead, WIMM

Professor Richard Houlston, Institute for Cancer Research, London

Professor Catherine Wu, Dana Farber, USA

Professor Torsten Zenz, Heidelberg Translational Oncology Facility, DKFZ, Germany

Professor Willem Ouweland, Cambridge

Professor Julie Makani, MUHAS

Professor Sam Mbuleiteye, NIH

Professor Anna Schuh graduated from Cologne Medical School and entered postgraduate training in the UK in 1994. After an extended period in research from 2000 to 2005 in Paris and the Weatherall Institute of Molecular Medicine, Oxford, she completed academic and clinical haematology training in Oxford. From 2006 to 2014 she was the NHS lead for all haematology laboratories and set-up a state-of-the-art molecular diagnostics service for patients with blood diseases or cancer. Her clinical focus has been with chronic lymphocytic leukaemia (CLL). As a result of her academic contributions to the field of precision diagnostics and CLL she was appointed to Associate Professor by the University in 2014.

Over the past twelve years Anna has led over 30 clinical trials in leukaemia as a principle or national chief investigator. A number of these led to NICE approvals, changing clinical practice for patients in the UK and worldwide. As a result, she was recently appointed as the Chair of Chronic Lymphocytic Leukaemia Research in the UK by the National Cancer Research Institute. Anna has also also chaired the UK CLL Forum from 2013 to 2016, and led the UK's guideline writing group for CLL Therapy on behalf of the British Society of Haematology.

Her second research interest is with the development, evaluation and implementation of new technologies for Precision Diagnostics. Her group published the first ever longitudinal study of the changes in the genomic landscape of patients undergoing treatment for leukaemia. She served as the Clinical Lead for the Oxford Genomics Medicine Centre from 2014 to 2017. She is the lead for the Genomics England Clinical Interpretation Partnership for haematological malignancies.

The current focus of her group is with the development of novel approaches to predict progression from pre-malignancy to malignant disease. She uses pre-malignant B-cell disorders and EBV-driven lymphomas in sub-Saharan Africa as exemplars.